PGFC
TEVA icon

Peapack-Gladstone Financial Corp’s Teva Pharmaceuticals TEVA Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$336K Sell
11,159
-648
-5% -$20.8K ﹤0.01% 562
2025
Q4 		$368K Sell
11,807
-2,375
-17% -$58.5K ﹤0.01% 547
2025
Q3 		$286K Buy
14,182
+3,782
+36% +$66.4K ﹤0.01% 589
2025
Q2 		$174K Buy
+10,400
New +$168K ﹤0.01% 651
2025
Q1 		– Sell
-10,677
Closed -$235K – 722
2024
Q4 		$235K Sell
10,677
-590
-5% -$10.7K ﹤0.01% 614
2024
Q3 		$203K Sell
11,267
-4,176
-27% -$73.1K ﹤0.01% 656
2024
Q2 		$251K Sell
15,443
-10,720
-41% -$165K ﹤0.01% 592
2024
Q1 		$369K Sell
26,163
-12,827
-33% -$162K 0.01% 535
2023
Q4 		$407K Sell
38,990
-17,518
-31% -$164K 0.01% 520
2023
Q3 		$576K Sell
56,508
-11,791
-17% -$110K 0.01% 450
2023
Q2 		$514K Sell
68,299
-5,411
-7% -$43.9K 0.01% 478
2023
Q1 		$652K Sell
73,710
-5,392
-7% -$53.3K 0.01% 431
2022
Q4 		$721K Sell
79,102
-2,251
-3% -$19.6K 0.01% 414
2022
Q3 		$657K Buy
81,353
+4,071
+5% +$36K 0.01% 420
2022
Q2 		$581K Buy
77,282
+3,106
+4% +$27.1K 0.01% 425
2022
Q1 		$697K Buy
74,176
+16,685
+29% +$139K 0.01% 416
2021
Q4 		$461K Buy
57,491
+7,429
+15% +$67.1K 0.01% 483
2021
Q3 		$488K Buy
50,062
+5,024
+11% +$47K 0.01% 470
2021
Q2 		$446K Sell
45,038
-627
-1% -$6.64K 0.01% 439
2021
Q1 		$527K Buy
+45,665
New +$524K 0.01% 401
2016
Q1 		– Sell
-4,205
Closed -$276K – 335
2015
Q4 		$276K Sell
4,205
-251
-6% -$15.5K 0.02% 281
2015
Q3 		$252K Sell
4,456
-550
-11% -$35.7K 0.02% 287
2015
Q2 		$296K Sell
5,006
-315
-6% -$19.4K 0.02% 270
2015
Q1 		$331K Buy
5,321
+1
+0% +$58 0.02% 264
2014
Q4 		$306K Sell
5,320
-285
-5% -$15.9K 0.02% 258
2014
Q3 		$301K Buy
5,605
+200
+4% +$10.6K 0.02% 250
2014
Q2 		$283K Buy
5,405
+470
+10% +$24K 0.02% 256
2014
Q1 		$261K Sell
4,935
-700
-12% -$32.4K 0.02% 265
2013
Q4 		$226K Sell
5,635
-40
-0.7% -$1.57K 0.02% 269
2013
Q3 		$214K Sell
5,675
-4,450
-44% -$174K 0.02% 270
2013
Q2 		$397K Buy
+10,125
New +$394K 0.04% 216

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Peapack-Gladstone Financial Corp's TEVA Position: Q1 2026 in Review

Peapack-Gladstone Financial Corp reduced its Teva Pharmaceuticals (TEVA) stake by 5.5% in Q1 2026, selling an estimated $20.8K and leaving 11,159 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #562.

Peapack-Gladstone Financial Corp first reported a position in TEVA in Q2 2013 and has held it in 31 quarters since. The position peaked at $721K in Q4 2022. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Peapack-Gladstone Financial Corp held 11,159 shares of Teva Pharmaceuticals worth $336K as of Q1 2026.
  • Peapack-Gladstone Financial Corp sold 648 Teva Pharmaceuticals shares in Q1 2026, an estimated $20.8K.
  • Teva Pharmaceuticals made up ﹤0.01% of Peapack-Gladstone Financial Corp's portfolio in Q1 2026, its #562 holding.
  • Peapack-Gladstone Financial Corp first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 31 quarters since.
  • Peapack-Gladstone Financial Corp's Teva Pharmaceuticals position peaked at $721K in Q4 2022.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q1 2026, filed 15 May 2026.